Interleukin-2 receptor (IL-2R), Human Recombinant Antibody

As low as US$477.00
Please choose unit size

Catalog Number
H-2031

    Product Info

  • Product Name Interleukin-2 receptor (IL-2R), Human Recombinant Antibody
  • Product Description google Human anti-Interleukin-2 receptor (IL-2R) Recombinant Antibody (Unconjugated), suitable for FC, Block, ICC, IHC, WB.
  • Alternative Names Interleukin-2 receptor subunit alpha; IL-2 receptor subunit alpha; IL-2R subunit alpha; IL-2-RA; IL2-RA; TAC antigen; p55; CD25.
  • Application(s) Block, FC, ICC, IHC, WB
  • Antibody Host Human
  • Antibody Type Recombinant
  • Specificity Basiliximab recognises the human IL-2R and binds to the epitope (116)ERIYHFV(122) within the extracellular domain of the CD25 subunit – binding is abolished when 2 or more residues within the epitope are mutated. This epitope overlaps with the interaction site of CD25 and IL-2. CD25 is found in the high-affinity IL-2R (αβγc) – T cells only express CD25 upon activation. IL-2 binding to IL-2R on T cells modulates proliferation and differentiation.
  • Species Reactivity Human, Primate
  • Immunogen Description Basiliximab was prepared by immunizing BALB/c mice with CTC 16 cells.
  • Conjugate Unconjugated
  • Concentration 1 mg/mL
  • Purity Description Purified antibody, via affinity chromatography
  • Regulatory Status For research use only.

    Specifications

  • Product Description Human anti-Interleukin-2 receptor (IL-2R) Recombinant Antibody (Unconjugated), suitable for FC, Block, ICC, IHC, WB.
  • Application(s) Block, FC, ICC, IHC, WB
  • Application Details Basiliximab is derived from the murine anti-Tac antibody. For the clinically used format, the variable regions from this antibody were grafted onto the sequence of the human IgG1κ constant regions. Basiliximab binding to CD25 competitively blocks the interaction of IL-2R with its ligand IL-2 on the surface of T cells. Blocking this interaction prevents T cell replication and T cell-mediated B cell activation. Basiliximab binding suppresses the immune system inhibits the pathway activating the cellular immune response to allograft rejection. IL-2 signalling suppression can additionally prevent acute graft-versus-host disease, autoimmune disorders and malignancies such as T cell leukemias (Binder et al, 2007). Basiliximab has also been used in FC, IF, IHC and WB studies, which enables the detection of CD25.
  • Target Interleukin-2 receptor (IL-2R)
  • Specificity Basiliximab recognises the human IL-2R and binds to the epitope (116)ERIYHFV(122) within the extracellular domain of the CD25 subunit – binding is abolished when 2 or more residues within the epitope are mutated. This epitope overlaps with the interaction site of CD25 and IL-2. CD25 is found in the high-affinity IL-2R (αβγc) – T cells only express CD25 upon activation. IL-2 binding to IL-2R on T cells modulates proliferation and differentiation.
  • Target Host Species Human
  • Species Reactivity Human, Primate
  • Antibody Host Human
  • Antibody Type Recombinant
  • Antibody Isotype IgG1, kappa
  • Clone Name Basiliximab
  • Conjugate Unconjugated
  • Immunogen Description Basiliximab was prepared by immunizing BALB/c mice with CTC 16 cells.
  • Purity Description Purified antibody, via affinity chromatography
  • Format Liquid. PBS with 0.02% Proclin 300.
  • Concentration 1 mg/mL
  • Storage Instructions Store at 2-8°C for up to 1 month. For longer storage, aliquot and store at -20_C. Avoid mulitiple freeze thaw cycles.
  • Batch Number Please see item label.
  • Expiration Date Store at 2-8⁰C for up to 3 months. For longer storage, aliquot and store at -20⁰C for up to 12 months.
  • Alternative Names Interleukin-2 receptor subunit alpha; IL-2 receptor subunit alpha; IL-2R subunit alpha; IL-2-RA; IL2-RA; TAC antigen; p55; CD25.
  • Uniprot Number P01589
  • Uniprot Number/Name P01589 (IL2RA_HUMAN)
  • Scientific Background NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. This is a chimeric antibody created for improved compatibility with existing reagents, assays and techniques. Basiliximab is derived from the murine anti-Tac antibody. For the clinically used format, the variable regions from this antibody were grafted onto the sequence of the human IgG1 constant regions. Basiliximab binding to CD25 competitively blocks the interaction of IL-2R with its ligand IL-2 on the surface of T cells. Blocking this interaction prevents T cell replication and T cell-mediated B cell activation. Basiliximab binding suppresses the immune system inhibits the pathway activating the cellular immune response to allograft rejection. IL-2 signalling suppression can additionally prevent acute graft-versus-host disease, autoimmune disorders and malignancies such as T cell leukemias (Binder et al, 2007). Basiliximab has also been used in FC, IF, IHC and WB studies, which enables the detection of CD25.
  • Shipping Temperature 2-8°C (on cold packs)
  • UNSPSC CODE 41116161
  • Regulatory Status For research use only.

    Images, Protocols & SDS

    Citations & References